To the Editor:
Life-threatening allergic reactions are characterized by allergen-specific IgE antibodies, whereas IgG antibodies are a default response to an antigen exposure. Subclass 4 IgG antibodies function as blocking antibodies, which may suppress IgE-mediated reactions. 1 Peanut oral immunotherapy (OIT), as other allergen immunotherapies, induces IgG4 antibodies. 2, 3 We have previously shown the increase of IgG4 to peanut seed storage proteins, and the dose-dependent increase of IgG4-IgE ratios in children and adolescents receiving peanut OIT. 4, 5 Further, we showed that IgE to the 2S albumins Ara h 2 and Ara h 6, which are the most important peanut allergens, 6 were the only IgE responses affected during OIT. 5 In this study, we screened IgG4 responses for a wide spectrum of allergens with the ISAC ImmunoCAP microarray in children and adolescents who underwent peanut OIT. We examined the IgG4 responses baseline and after OIT build-up phase with the aim of finding effects of the treatment on IgG4 responses to peanut-specific and cross-reactive allergens.
The study population has been described in our previous publications. 4, 5 Briefly, 6-to 18-year-old children and adolescents were referred to the hospital because of peanut allergy. Of them, 39 with a moderate-to-severe reaction in a double-blind placebo-controlled peanut
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challenge started OIT and 21 control patients continued to avoid peanut. During OIT, the daily dose of peanut protein increased from 0.1 to 800 mg in eight months. Serum samples were drawn at baseline and after median 12 months of OIT build-up phase or avoidance. We analyzed serum IgG4 (30 µl of sample) in ImmunoCAP ISAC microarrays (ThermoFisher Scientific; Uppsala, Sweden). We considered the detection limit 0.1 ISU-G4 also as cut-off for positive response. The ethics committee of Helsinki University Hospital approved the study. One of the parents and the patient gave a written informed consent.
In analyzing repeated measures of the 112 allergens, we filtered the results so that in order to be included in the analysis an allergen had to show value above detection limit 0.1 (ISU-G4) in at least 50% + 1 of the patients in at least one of the four groups (pre OIT, post OIT, pre avoidance, post avoidance). We fitted a linear model to investigate the effects of treatment, response, subject, sex, and age. Furthermore, we used the eBayes test for pairwise comparisons of interest. P values were corrected in each pairwise comparison by using the Benjamini-Hochberg procedure. We used R 
This article is protected by copyright. All rights reserved. To our knowledge this is the first study to examine microarrayed IgG4 profiles in patients who received peanut oral immunotherapy. During the treatment, the only IgG4 levels to change were peanut seed storage proteins Ara h 1, 2, and 6. This is in line with our previous study were peanut OIT affected IgE only for the 2S albumins Ara h 2 and 6. However, in the IgG4 antibodies, the effect included also a third seed storage protein, Ara h 1. Studies on peanut sensitization and allergy show that the 7S globulin Ara h 1 is more associated with peanut allergy than the 11S globulin Ara h 3. 7, 8 In our previous study, IgG4, measured with ImmunoCAP, showed increases in Ara h 1 and Ara h 3, of which Ara h 1-change was stronger. 5 In the present study, Ara h 3-response in IgG4 ISAC was underrepresented and therefore conclusions on effects on this allergen are limited. However, the response rate increased from 15% before OIT to 44% after OIT. (Table 1 b) We believe that mild increase in Ara h 3 IgG4 in ISAC is possible.
The findings of unaffected Ara h 8-and Ara h 9-IgG4-levels are similar to our previous study on IgE microarray profiles in this patient population. 5 Ara h 8 is degraded in the gastric digestion and its' effects on IgG4 levels may be therefore limited. The amount of lipid transfer protein Ara h 9 is low in peanut 9 which in turn may decrease the immunological effects of this stable allergen. Both Ara h 8-and 9-IgG4 responses were infrequent in our study population.
Considering the development of tolerance, IgG4 may be the most important immunoglobulin in immunotherapy. Findings of this study further highlight the specificity of immunological response in peanut oral immunotherapy as IgG4 effects seem to occur only on the most peanut-specific allergens, but not on cross-reactive or unrelated allergens.
This article is protected by copyright. All rights reserved. 
